207 related articles for article (PubMed ID: 12694169)
1. Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath-1H.
Rodon P; Breton P; Courouble G
Eur J Haematol; 2003 May; 70(5):319-21. PubMed ID: 12694169
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H).
Ru X; Liebman HA
Br J Haematol; 2003 Oct; 123(2):278-81. PubMed ID: 14531909
[TBL] [Abstract][Full Text] [Related]
3. The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
Willis F; Marsh JC; Bevan DH; Killick SB; Lucas G; Griffiths R; Ouwehand W; Hale G; Waldmann H; Gordon-Smith EC
Br J Haematol; 2001 Sep; 114(4):891-8. PubMed ID: 11564082
[TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab for B-cell chronic lymphocytic leukemia.
Robak T
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1033-51. PubMed ID: 18588450
[TBL] [Abstract][Full Text] [Related]
5. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody).
Karlsson C; Hansson L; Celsing F; Lundin J
Leukemia; 2007 Mar; 21(3):511-4. PubMed ID: 17215854
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia.
Lundin J; Karlsson C; Celsing F
Med Oncol; 2006; 23(1):137-9. PubMed ID: 16645240
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed?
Rieger K; Von Grünhagen U; Fietz T; Thiel E; Knauf W
Leuk Lymphoma; 2004 Feb; 45(2):345-9. PubMed ID: 15101722
[TBL] [Abstract][Full Text] [Related]
8. CAMPATH-1H in the treatment of autoimmune cytopenias.
Marsh JC; Gordon-Smith EC
Cytotherapy; 2001; 3(3):189-95. PubMed ID: 12171725
[TBL] [Abstract][Full Text] [Related]
9. Campath-1H induced pure red cell aplasia in a patient with chronic lymphatic leukaemia.
Thachil J; Salim R
Leuk Res; 2007 Jul; 31(7):1025-6. PubMed ID: 17005249
[No Abstract] [Full Text] [Related]
10. Alemtuzumab therapy in B-cell lymphoproliferative disorders.
Moreton P; Hillmen P
Semin Oncol; 2003 Aug; 30(4):493-501. PubMed ID: 12939718
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia.
Bowen AL; Zomas A; Emmett E; Matutes E; Dyer MJ; Catovsky D
Br J Haematol; 1997 Mar; 96(3):617-9. PubMed ID: 9054672
[TBL] [Abstract][Full Text] [Related]
12. In vivo 'purging' of residual disease in CLL with Campath-1H.
Dyer MJ; Kelsey SM; Mackay HJ; Emmett E; Thornton P; Hale G; Waldmann H; Newland AC; Catovsky D
Br J Haematol; 1997 Jun; 97(3):669-72. PubMed ID: 9207420
[TBL] [Abstract][Full Text] [Related]
13. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab.
Elter T; Vehreschild JJ; Gribben J; Cornely OA; Engert A; Hallek M
Ann Hematol; 2009 Feb; 88(2):121-32. PubMed ID: 18682948
[TBL] [Abstract][Full Text] [Related]
14. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia.
Diehl LF; Ketchum LH
Semin Oncol; 1998 Feb; 25(1):80-97. PubMed ID: 9482530
[TBL] [Abstract][Full Text] [Related]
15. Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients.
Elimelakh M; Dayton V; Park KS; Gruessner AC; Sutherland D; Howe RB; Reding MT; Eastlund T; van Burik JA; Singleton TP; Gruessner RW; Key NS
Haematologica; 2007 Aug; 92(8):1029-36. PubMed ID: 17640860
[TBL] [Abstract][Full Text] [Related]
16. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.
Osterborg A; Dyer MJ; Bunjes D; Pangalis GA; Bastion Y; Catovsky D; Mellstedt H
J Clin Oncol; 1997 Apr; 15(4):1567-74. PubMed ID: 9193354
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
Alinari L; Lapalombella R; Andritsos L; Baiocchi RA; Lin TS; Byrd JC
Oncogene; 2007 May; 26(25):3644-53. PubMed ID: 17530018
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.
Osterborg A; Karlsson C; Lundin J
Curr Hematol Malig Rep; 2009 Jan; 4(1):47-53. PubMed ID: 20425438
[TBL] [Abstract][Full Text] [Related]
19. Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Cavalli-Björkman N; Osby E; Lundin J; Kalin M; Osterborg A; Gruber A
Med Oncol; 2002; 19(4):277-80. PubMed ID: 12512923
[TBL] [Abstract][Full Text] [Related]
20. Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands.
Laros-van Gorkom BA; Huisman CA; Wijermans PW; Schipperus MR
Neth J Med; 2007 Oct; 65(9):333-8. PubMed ID: 17954952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
